Human Papillomavirus (HPV) News and Research

Latest Human Papillomavirus (HPV) News and Research

Conservatives and sexual abstinence groups battle with FDA over condoms - they offer little protection against STD's

Although condoms are an effective method of contraception and stop the spread of AIDS, evidence that they protect against other sexually transmitted diseases is scant.

30 Jun 2005

AAV2 has great potential to be developed as an anti-cancer agent

Six days is all it takes for a common, non-disease-causing virus to kill cervical, breast, prostate and squamous cell cancer cells in laboratory cultures, according to Penn State College of Medicine researchers.

21 Jun 2005

Incorporating human papillomavirus testing into cervical cancer screening will provide health benefits at a reasonable cost

Incorporating testing for human papillomavirus (HPV) DNA into cervical cancer screening has the potential for improving health benefits at a reasonable cost in France, Italy, the Netherlands, and the United Kingdom, according to a new study in the June 15 issue of the Journal of the National Cancer Institute.

14 Jun 2005

Researchers may be on the verge of exploiting the vulnerabilities of a virus that causes cervical cancer

Researchers may be on the verge of exploiting the vulnerabilities of a virus that causes cervical cancer, thanks to a newly developed technique that enables scientists to mass-produce human papillomavirus (HPV) in the laboratory.

13 Jun 2005

Research accelerates the search for an effective cancer vaccine

By devising a novel way to package the genome of a common human tumor virus - the virus that causes common warts, genital warts and that is implicated in prevalent cancers - scientists have paved the way for making the pathogen far more accessible to biomedical science.

13 Jun 2005

Home test kits provide young women with a safe and effective means for protecting their sexual reproductive health

Researchers at Johns Hopkins say they have evidence that more than one-third of young women are willing and able to use a free, easily available home test kit to privately and accurately learn if they are infected with Chlamydia trachomatis, the most common sexually transmitted disease (STD) in this group.

8 Jun 2005

Helix opens additional sites for its Topical Interferon Alpha-2b Phase II clinical study

Helix BioPharma announced today the opening of two additional German sites for the Phase II clinical trial of its Topical Interferon Alpha-2b product at the Charité Berlin, one of the largest university hospitals in Europe.

2 Jun 2005

Merck cervical cancer virus vaccine performs well

Drugmaker Merck & Co. Inc. on Thursday said its investigational vaccine against a sexually transmitted virus linked to cervical cancer triggered a stronger immune response in young adolescents than in young women in a late-stage trial.

20 May 2005

Cervical cancer virus vaccine appears very promising

Gardasil, a vaccine created by drugmaker Merck & Co which aims to protect against a sexually transmitted virus linked to cervical cancer, triggered a stronger immune response in young adolescents than in young women in a late-stage trial.

19 May 2005

Intralesional immunotherapy for common warts is effective and safe

Injection of skin test antigens (preparations used in skin tests for immunity) into warts appears to stimulate the immune system and successfully treat the injected wart and also helps to treat distant non-injected warts, according to a study in the May issue of Archives of Dermatology.

16 May 2005

New treatments for common vaginal infection being studied

Whether a two-week regimen using a stainless steel douching device can eradicate the most common vaginal infection is under study at the Medical College of Georgia.

9 May 2005

New cervical cancer drug could be a bestseller

New data released yesterday says that a new vaccine that promises to protect against cervical cancer could offer wider resistance to the disease than previously thought.

5 May 2005

GlaxoSmithKline to acquire Corixa Corporation

GlaxoSmithKline has announced the execution of a definitive agreement pursuant to which GSK will acquire Corixa Corporation, a developer of innovative products that regulate immunity, based in Seattle, WA (USA).

2 May 2005

Aging population correlates with a switch from acute infectious diseases to chronic diseases as the major cause of morbidity and mortality

Some diseases like ulcers and certain types of cancer, once thought to be primarily related to lifestyle factors, are now known to be caused by microorganisms, and many more syndromes, including some psychiatric conditions, may have a connection to infection, according to a report released today by the American Academy of Microbiology.

22 Apr 2005

Rates of cervical cancer could jump fourfold to a million a year by 2050

Deaths from cervical cancer could jump fourfold to a million a year by 2050, mainly in developing countries. This could be prevented by soon-to-be-approved vaccines against the virus that causes most cases of cervical cancer- but there are signs that opposition to the vaccines might lead to many preventable deaths. The trouble is that the human papilloma virus (HPV) is sexually transmitted.

13 Apr 2005

Vaccine against the virus that causes cervical cancer and genital warts shows promise

A vaccine against the virus that causes cervical cancer and genital warts could reduce persistent infection and disease by 90%, suggest the results of a randomised trial published online by The Lancet Oncology.

12 Apr 2005

UAB reaction to Lancet study on human papilloma virus (HPV)

The prominent British medical journal Lancet published results of a clinical trial on a vaccine for human papilloma virus (HPV) The virus is a leading cause of cervical cancer and genital warts.

10 Apr 2005

Race to market cancer vaccine

In a race to market the first vaccine against the virus that causes cervical cancer and genital warts drug manufacturers Merck & Co Inc. and GlaxoSmithKline plc are in head-to-head competition.

7 Apr 2005

Vaccine against cervical cancer and genital warts looks hopeful

More than two thirds of sexually active women will become infected with human papillomavirus (HPV) during their lifetime. HPV causes around 470 000 cases of cervical cancer each year and even though most cases of cervical cancer occur in the developing world, where cervical screening programmes are in the main non-existent, in Europe and the US 35000 women die from the disease every year.

6 Apr 2005

Certain combinations of genes increase the risk of developing cervical cancer

Certain combinations of genes that encode receptors on innate immune cells increase the risk of developing cervical cancer, according to a study by Mary Carrington and colleagues in the April 4 issue of The Journal of Experimental Medicine.

4 Apr 2005